Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma.
In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.
The Lautenberg Center for Immunology; IMRIC, Hebrew University - Hadassah Medical School ; Jerusalem, Israel.
Elad
E
Horwitz
The Lautenberg Center for Immunology; IMRIC, Hebrew University - Hadassah Medical School; Jerusalem, Israel; Department of Pathology; Hadassah-Hebrew University Medical Center; Jerusalem, Israel.
Ilan
I
Stein
The Lautenberg Center for Immunology; IMRIC, Hebrew University - Hadassah Medical School ; Jerusalem, Israel.
Yinon
Y
Ben-Neriah
The Lautenberg Center for Immunology; IMRIC, Hebrew University - Hadassah Medical School; Jerusalem, Israel; Department of Pathology; Hadassah-Hebrew University Medical Center; Jerusalem, Israel.
Eli
E
Pikarsky
HCC; VEGFA; copy number variation; genomic amplification; macrophages; mouse model; sorafenib